Unjoni Ewropea - Malti - EMA (European Medicines Agency)

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - aġenti antineoplastiċi - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimikotiċi għal użu sistemiku - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

teva b.v. - reslizumab - ażma - mediċini sistemiċi oħrajn għall-imblokkar tal-passaġġ tan-nifs mard, - cinqaero huwa indikat bħala terapija iż-żieda fil-pazjenti adulti bl-asthma eosinophilic severi mhux ikkontrollat minkejja doża għolja ġewwa man-nifs corticosteroids biż- żieda ta ' prodott mediċinali ieħor għat-trattament ta ' manutenzjoni.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

basilea pharmaceutica deutschland gmbh - isavuconazole - asperġillożi - cresemba huwa indikat fl-adulti għall-kura ta': invażivi aspergillosismucormycosis fil-pazjenti li għalihom amphotericin b huwa inappropriateconsideration għandha tingħata lill-gwida uffiċjali dwar l-użu xieraq ta ' mediċini antifungali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi winthrop industrie - rasburicase - iperurċemija - il-prodotti terapewtiċi l-oħra kollha - it-trattament u l-profilassi ta ' hyperuricaemia akuta, sabiex jiġi evitat falliment renali akuta, fl-adulti, tfal u adolexxenti (età 0 sa 17 snin) ma malignancy ħematoloġiċi mal-piż tumur għolja u f'riskju tumur rapida lysis jew jinxtorob fil bidu ta ' l-chemotherapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

les laboratoires servier - irinotecan anhydrous free-base - neoplażmi pankreatiċi - aġenti antineoplastiċi - trattament ta ' adenocarcinoma metastatic ta-pancreas, flimkien ma ' 5 fluorouracil (artikolu 5) u leucovorin (lv), fil-pazjenti adulti li wettqu wara gemcitabine bbażati fuq terapija.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

teva b.v. - tacrolimus monohydrate - liver transplantation; kidney transplantation - immunosoppressanti - profilassi tar-rifjut tat-trapjanti f'riċevituri ta 'l-alloġib tal-kliewi jew tal-fwied adulti. kura ta 'rifjut tal-allograft reżistenti għat-trattament ma' prodotti mediċinali immunosoppressivi oħra f'pazjenti adulti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

accord healthcare s.l.u. - posaconazole - mikosijiet - antimikotiċi għal użu sistemiku - posaconazole ahcl suspensjoni orali huwa indikat għall-użu fil-kura ta ' l-infezzjonijiet tal-fungu fl-adulti:asperġillożi invażiva f'pazjenti b'mard li hu refrattarju għal amphotericin b jew itraconazole jew f'pazjenti intolleranti għal dawn il-prodotti mediċinali;fusarjożi f'pazjenti b'mard li hu refrattarju għal amphotericin b jew f'pazjenti intolleranti għal amphotericin b;kromoblastomikożi u miċetoma f'pazjenti b'mard li hu refrattarju għal itraconazole jew f'pazjenti intolleranti għal itraconazole;kokkidajojdomikożi f'pazjenti b'mard li hu refrattarju għal amphotericin b, itraconazole jew fluconazole jew f'pazjenti intolleranti għal dawn il-prodotti mediċinali. kandidijażi orofarinġali: bħala l-kura preferita f'pazjenti li għandhom mard sever jew li huma immunokompromessi, li r-rispons għal terapija topika hija mistennija li tkun fqir. ir-refrattorjetà hija definita bħala l-progressjoni tal-infezzjoni jew nuqqas ta 'titjib wara minimu ta' 7 ijiem ta 'dożi terapewtiċi preċedenti ta' terapija antifungali effettiva. posaconazole ahcl suspensjoni orali huwa indikat ukoll għal profilassi ta 'infezzjonijiet fungali invażivi fil-pazjenti li ġejjin:pazjenti li kienu qed jirċievu remissjoni-induzzjoni ta' kimoterapija għal lewkimja majeloġenuża akuta (aml) jew għal sindromi majelodisplastiċi (mds) mistennija li jikkawżaw newtropenja u li huma f'riskju għoli li jiżviluppaw infezzjonijiet tal-fungu invażivi;trapjant ta'ċelloli staminali ematopojetiċi (hsct) riċevituri li huma għaddejjin minn doża għolja ta ' terapija immunosopprimenti għal-graft kontra l-host u li huma f'riskju għoli li jiżviluppaw infezzjonijiet invażivi tal-fungu.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - aġenti antineoplastiċi - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.